205 related articles for article (PubMed ID: 7545705)
1. Short-contact anthralin treatment augments therapeutic efficacy of cyclosporine in psoriasis: a clinical and pathologic study.
Gottlieb SL; Heftler NS; Gilleaudeau P; Johnson R; Vallat VP; Wolfe J; Gottlieb AB; Krueger JG
J Am Acad Dermatol; 1995 Oct; 33(4):637-45. PubMed ID: 7545705
[TBL] [Abstract][Full Text] [Related]
2. Alteration of the expression of Bcl-2, Bcl-x, Bax, Fas, and Fas ligand in the involved skin of psoriasis vulgaris following topical anthralin therapy.
Yamamoto T; Nishioka K
Skin Pharmacol Appl Skin Physiol; 2003; 16(1):50-8. PubMed ID: 12566829
[TBL] [Abstract][Full Text] [Related]
3. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement.
Mahrle G; Schulze HJ; Färber L; Weidinger G; Steigleder GK
J Am Acad Dermatol; 1995 Jan; 32(1):78-88. PubMed ID: 7822521
[TBL] [Abstract][Full Text] [Related]
4. Anthralin modulates the expression pattern of cytokeratins and antimicrobial peptides by psoriatic keratinocytes.
Holstein J; Fehrenbacher B; Brück J; Müller-Hermelink E; Schäfer I; Carevic M; Schittek B; Schaller M; Ghoreschi K; Eberle FC
J Dermatol Sci; 2017 Sep; 87(3):236-245. PubMed ID: 28673488
[TBL] [Abstract][Full Text] [Related]
5. The influence of a topical corticosteroid on short-contact high-dose dithranol therapy.
Swinkels OQ; Prins M; Tosserams EF; Gerritsen MJ; Van Der Valk PG; Van De Kerkhof PC
Br J Dermatol; 2001 Jul; 145(1):63-9. PubMed ID: 11453908
[TBL] [Abstract][Full Text] [Related]
6. Short contact anthralin in the treatment of psoriasis: a study of different contact times.
MacDonald KJ; Marks J
Br J Dermatol; 1986 Feb; 114(2):235-9. PubMed ID: 3947539
[TBL] [Abstract][Full Text] [Related]
7. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation.
Gottlieb AB; Grossman RM; Khandke L; Carter DM; Sehgal PB; Fu SM; Granelli-Piperno A; Rivas M; Barazani L; Krueger JG
J Invest Dermatol; 1992 Mar; 98(3):302-9. PubMed ID: 1372027
[TBL] [Abstract][Full Text] [Related]
8. Anthralin for psoriasis: short-contact anthralin therapy compared with topical steroid and conventional anthralin.
Lowe NJ; Ashton RE; Koudsi H; Verschoore M; Schaefer H
J Am Acad Dermatol; 1984 Jan; 10(1):69-72. PubMed ID: 6693604
[TBL] [Abstract][Full Text] [Related]
9. Cytokinetic effects of anthralin on psoriatic keratinocytes.
Pullmann H; Enderer K; Steigleder GK
Br J Dermatol; 1981 Aug; 105 Suppl 20():55-6. PubMed ID: 6169362
[No Abstract] [Full Text] [Related]
10. Epidermal differentiation characteristics of the psoriatic plaque during short contact treatment with dithranol cream.
van der Vleuten CJ; de Jong EM; van de Kerkhof PC
Clin Exp Dermatol; 1996 Nov; 21(6):409-14. PubMed ID: 9167334
[TBL] [Abstract][Full Text] [Related]
11. Low strength anthralin in psoriasis.
Montes LF; Wilborn WH; Brody I
J Cutan Pathol; 1979 Dec; 6(6):445-56. PubMed ID: 42654
[TBL] [Abstract][Full Text] [Related]
12. Remission of ordinary psoriasis following a short clearance course of cyclosporin.
Levell NJ; Shuster S; Munro CS; Friedmann PS
Acta Derm Venereol; 1995 Jan; 75(1):65-9. PubMed ID: 7747540
[TBL] [Abstract][Full Text] [Related]
13. Combining lesional short-contact dithranol therapy of psoriasis with a potent topical corticosteroid.
Swinkels OQ; Prins M; Kucharekova M; de Boo T; Gerritsen MJ; van der Valk PG; van de Kerkhof PC
Br J Dermatol; 2002 Apr; 146(4):621-6. PubMed ID: 11966693
[TBL] [Abstract][Full Text] [Related]
14. Fluorescence remission spectroscopy of psoriatic lesions and the effect of topical anthralin therapy.
Wollina U; Schmidt WD; Koch A; Scheibe A; Erfurth F; Fassler D
J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1409-13. PubMed ID: 19508501
[TBL] [Abstract][Full Text] [Related]
15. Measurement of the response of psoriasis to short-term application of anthralin.
Marsden JR; Coburn PR; Marks J; Shuster S
Br J Dermatol; 1983 Aug; 109(2):209-18. PubMed ID: 6871098
[TBL] [Abstract][Full Text] [Related]
16. [Anthralin therapy of psoriasis--a retrospective study of 39 cases].
Higashi K; Katayama I; Nishioka K; Nishiyama S
Nihon Hifuka Gakkai Zasshi; 1989 Feb; 99(2):129-34. PubMed ID: 2746967
[TBL] [Abstract][Full Text] [Related]
17. [Effect of the treatment of psoriasis with dithranol in comparison with a combination of dithranol and a corticosteroid].
Gloor M; Graf R; Wirth H; Landau M
Hautarzt; 1983 Oct; 34(10):500-3. PubMed ID: 6643055
[TBL] [Abstract][Full Text] [Related]
18. Detection of anthralin in skin during treatment.
Juhlin L; Schroot B
Acta Derm Venereol Suppl (Stockh); 1985; 120():27-9. PubMed ID: 3869415
[TBL] [Abstract][Full Text] [Related]
19. Epidermal calmodulin levels in psoriasis before & after therapy.
Kaur I; Kaur S; Vaishnavi C; Ganguly NK; Garg J; Kohli M
Indian J Med Res; 1991 Apr; 94():130-3. PubMed ID: 1879887
[TBL] [Abstract][Full Text] [Related]
20. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy.
Vallat VP; Gilleaudeau P; Battat L; Wolfe J; Nabeya R; Heftler N; Hodak E; Gottlieb AB; Krueger JG
J Exp Med; 1994 Jul; 180(1):283-96. PubMed ID: 7516410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
